53 results
Keyword Ipilimumab Remove keyword
-
List item
Press release: New treatment option recommended for patients with advanced melanoma
CHMP, Last updated: 22/05/2015other comparing Keytruda with ipilimumab, another melanoma treatment … had not previously received ipilimumab and in patients who had previously … who had previously received ipilimumab. The Committee also looked … -
List item
National expert: Paolo Antonio Ascierto, European Medicines Agency (updated)
- Declaration of interests - 91.63 KB | PDF
- Curriculum Vitae - 71.52 KB | PDF
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic … Ascierto PA, Pilla L, et al. Ipilimumab and fotemustine in patients … PA. Efficacy and safety of ipilimumab in patients with pre-treated … -
List item
National expert: Piotr Rutkowski, European Medicines Agency (updated)
- Declaration of interests - 85.01 KB | PDF
- Curriculum Vitae - 29.65 KB | PDF
01/2015-(current) BMS nivolumab, ipilimumab melanoma 01/2019-(current … melanoma 05/2013-(current) BMS ipilimumab melanoma 01/2012-(current … 01/2013-(current) BMS nivolumab, ipilimumab, dacarbazine melanoma … -
List item
National expert: Mark van Bussel, Medicines Evaluation Board (updated)
- Declaration of interests - 80.55 KB | PDF
- Curriculum Vitae - 17.82 KB | PDF
responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic … -
List item
Press release: European Medicines Agency recommends approval of Tafinlar for the treatment of metastatic melanoma
CHMP, Last updated: 28/06/2013them, the monoclonal antibody ipilimumab, targets a molecule found … them, the monoclonal antibody ipilimumab, targets a molecule found … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2020
CHMP, Last updated: 28/02/2020ipilimumab) in the treatment of metastatic … -
List item
National expert: Bjorg Bolstad, Norwegian Medicines Agency (updated)
- Declaration of interests - 82.09 KB | PDF
- Curriculum Vitae - 19.95 KB | PDF
with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk … -
List item
National expert: Aranzazu Sancho-Lopez, Spanish Agency of Medicines and Medical Devices (updated)
- Declaration of interests - 81.95 KB | PDF
- Curriculum Vitae - 20.31 KB | PDF
medicines Agency review of ipilimumab (Yervoy) for the treatment … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 November 2018
CHMP, Last updated: 16/11/2018ipilimumab) in combination to treat … -
List item
National expert: Lothar Bergmann, Paul-Ehrlich-Institute (updated)
- Declaration of interests - 82.42 KB | PDF
- Curriculum Vitae - 17.96 KB | PDF
-
List item
National expert: Bozenna Dembowska-Baginska, The Office for Registration of Medicinal Products, Medical Devices and Biocides (updated)
- Declaration of interests - 83.94 KB | PDF
- Curriculum Vitae - 74.23 KB | PDF
11/2017-07/2020 BMS Nivolumab, Ipilimumab High Grade Primary CNS Malignancies … -
List item
National expert: Paula Boudewina van Hennik, Medicines Evaluation Board (updated)
- Declaration of interests - 79.79 KB | PDF
- Curriculum Vitae - 23.29 KB | PDF
-
List item
Press release: European Medicines Agency recommends approval of Mekinist for the treatment of melanoma
CHMP, Last updated: 25/04/2014including a monoclonal antibody (ipilimumab) that targets a molecule … a monoclonal antibody (ipilimumab) that targets a molecule … -
List item
National expert: Kyrre Eeg Emblem, European Medicines Agency (updated)
- Declaration of interests - 81.14 KB | PDF
- Curriculum Vitae - 43.36 KB | PDF
-
List item
National expert: Maja Sommerfelt Grønvold, Norwegian Medicines Agency (updated)
- Declaration of interests - 81.78 KB | PDF
- Curriculum Vitae - 29.18 KB | PDF
with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2018
CHMP, Last updated: 21/09/2018ipilimumab) have requested re-examination … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018
CHMP, Last updated: 27/07/2018ipilimumab) in combination to treat … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2018
CHMP, Last updated: 27/04/2018Name of medicine Yervoy INN ipilimumab Marketing-authorisation holder … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2017
CHMP, Last updated: 15/12/2017Name of medicine Yervoy INN ipilimumab Marketing-authorisation holder … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2013
CHMP, Last updated: 20/09/2013Yervoy INN ipilimumab Marketing-authorisation holder … -
List item
Press release: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2011
CHMP, Last updated: 20/05/2011ipilimumab), from Bristol-Myers Squibb … 210 days. • Yervoy (ipilimumab), from Bristol-Myers Squibb … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 September 2020
CHMP, Last updated: 18/09/2020Yervoy INN ipilimumab Marketing-authorisation applicant … -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 15/01/2021 -
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 07/01/2021 -
List item
PDCO: Agendas, minutes and meeting reports
Last updated: 11/11/2020